Pfizer on the Street: Analyst Ratings and Recommendations



Wall Street analyst estimates

Wall Street analysts estimate that Pfizer’s (PFE) top line will rise 1% YoY (year-over-year) to ~$13.18 billion in 3Q17. Its EPS (earnings per share) are expected to rise to $0.64.

Article continues below advertisement

Analysts’ ratings

Pfizer’s stock price has risen nearly 9.6% over the 12 months. Analysts’ estimates show that the stock has a potential to return ~7.7% during that period, and the recommendations show a 12-month target price of $38.35 per share, compared with $35.6 on October 27.

Analyst recommendations

As of October 29, 2017, of the 21 analysts tracking Pfizer, 12 analysts recommend a “buy,” eight recommend a “hold,” while one recommends a “sell” for the stock. The consensus rating for Pfizer stands at 2.48, which represents a moderate buy for value investors.

Remember, changes in analysts’ estimates and recommendations are based on the changing trends in stock price and the performance of the company.

Pfizer’s valuation

On October 29, 2017, Pfizer was trading at a forward PE of 13.1x, compared with the industry average of 17.7x. Pfizer is trading at a forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) ratio of 10.7x, compared with the industry average of 13.7x.

Notably, the Vanguard Health Care ETF (VHT) has 40.0% of its total assets in pharmaceutical companies. VHT has 5.5% of its total assets in Pfizer (PFE), 3.6% in Amgen (AMGN), 3.0% in Celgene (CELG), and 3.1% in AbbVie (ABBV).


More From Market Realist